IRIS
SEGALA, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3608
EU - Europa 2061
AS - Asia 529
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 5
OC - Oceania 3
AF - Africa 2
Totale 6214
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3601
IT - Italia 896
PL - Polonia 715
CN - Cina 368
DE - Germania 109
UA - Ucraina 95
SE - Svezia 86
GB - Regno Unito 78
VN - Vietnam 69
TR - Turchia 64
FR - Francia 31
FI - Finlandia 22
IN - India 12
BE - Belgio 11
CA - Canada 6
EU - Europa 5
KR - Corea 5
IE - Irlanda 4
AU - Australia 3
CH - Svizzera 3
IR - Iran 3
NL - Olanda 3
BR - Brasile 2
CL - Cile 2
RU - Federazione Russa 2
ZA - Sudafrica 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GE - Georgia 1
HK - Hong Kong 1
IL - Israele 1
IQ - Iraq 1
JP - Giappone 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SM - San Marino 1
TH - Thailandia 1
Totale 6214
Salva come PNG Salva come JPEG
Città #
Warsaw 715
Fairfield 588
Chandler 356
Woodbridge 309
Beijing 245
Houston 236
Wilmington 236
Ashburn 226
Seattle 216
Cambridge 176
Princeton 155
Ferrara 123
Ann Arbor 111
Jacksonville 102
Dong Ket 69
San Diego 69
Bremen 60
Milan 56
Izmir 47
Falls Church 37
Nanjing 37
Redwood City 31
Dearborn 27
Addison 26
Santa Maria Di Sala 22
London 20
Boardman 17
Rome 17
Norwalk 16
Mountain View 15
San Mateo 15
Bologna 13
Shenyang 10
Brussels 9
Nanchang 9
Tianjin 9
Augusta 7
Jiaxing 7
Chicago 6
Hebei 6
Helsinki 6
Jinan 6
Andover 5
Auburn Hills 5
Castelnuovo Rangone 5
Cordenons 5
Ferrara di Monte Baldo 5
Palermo 5
Philadelphia 5
Taizhou 5
Arezzo 4
Florence 4
Hangzhou 4
Padova 4
Pisa 4
Torino 4
Verona 4
Zonguldak 4
Cascina 3
Catania 3
Chilly-mazarin 3
Des Moines 3
Guangzhou 3
Haikou 3
Kunming 3
Leawood 3
Mumbai 3
North Wales 3
Trieste 3
Venezia 3
Wuhan 3
Ardabil 2
Camparada 2
Campobasso 2
Changchun 2
Copparo 2
Dublin 2
Floridia 2
Genoa 2
Genova 2
Lanzhou 2
Napoli 2
New Delhi 2
Ningbo 2
Parma 2
Pavullo Nel Frignano 2
Ravenna 2
Rimini 2
Romano 2
San Giorgio A Cremano 2
Simi Valley 2
Taiyuan 2
Teramo 2
Teulada 2
Trento 2
Treviso 2
Verolanuova 2
Vicenza 2
Zhengzhou 2
Afragola 1
Totale 4631
Salva come PNG Salva come JPEG
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 391
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 246
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 155
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 113
null 106
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 102
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 96
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 88
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 84
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 83
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 81
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 79
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 70
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 69
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 67
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 66
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 65
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 64
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 62
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 62
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 62
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 61
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 60
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 60
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 59
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 59
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 59
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 57
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 57
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 56
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 56
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 56
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 56
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 56
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 55
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 55
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 54
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 54
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 54
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 53
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 53
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 53
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 53
null 53
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 53
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 53
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 52
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 51
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 51
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 50
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 50
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 50
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 50
FOLLOW-UP SIEROLOGICO DI PAZIENTE AFFETTO DA RECIDIVA DI IDATIDOSI EPATICA ED INTOLLERANZA ALL’ALBENDAZOLO (ABZ). 49
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 49
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 49
null 48
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 48
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 48
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 48
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 48
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 47
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 47
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 46
null 46
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 44
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 44
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 43
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 41
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 41
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 40
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 40
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 40
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 39
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 39
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 39
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 38
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 37
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 36
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 35
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 35
Associations between immune depression and cardiovascular events in HIV infection 35
RIACUTIZZAZIONE DI EPATITE CRONICA HBV-RELATA DOPO VACCINAZIONE ANTINFLUENZALE. DESCRIZIONE DI UN CASO CLINICO 34
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 34
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 34
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics 33
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 33
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens 33
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 32
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 32
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 31
Impact of lamivudine monotherapy in failing patients with multidrug-resistant HIV: final 48 weeks results (MONO-AIFA FARM7PAZS3) 30
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 29
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 29
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 29
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients 29
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 28
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 28
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 28
La applicazione delle Linee Guida Italiane di terapia antiretrovirale nella realtà ambulatoriale: efficacia e tollerabilità della cART di prima linea. 27
Totale 5752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17864
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 298
Totale 18162
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201874 0000 00 00 20301113
2018/2019325 915519 1010 3514 45462295
2019/20201270 5910638 1838 4633 404295160163
2020/20212586 143271132313 301303 224213 12631089161
2021/20221092 74972315 5789 5666 3812253402
2022/2023890 159666854 17793 57101 115000
Totale 6544